CSIMarket Company Name, Ticker, Suppliers, else..
 
Lucira Health Inc   (LHDX)
Other Ticker:  
 
 
Price: $0.4523 $-0.11 -19.232%
Day's High: $0.578 Week Perf: -11.31 %
Day's Low: $ 0.43 30 Day Perf: 15.32 %
Volume (M): 37,065 52 Wk High: $ 1.45
Volume (M$): $ 16,764 52 Wk Avg: $0.53
Open: $0.49 52 Wk Low: $0.11



 Market Capitalization (Millions $) 18
 Shares Outstanding (Millions) 40
 Employees 100
 Revenues (TTM) (Millions $) 212
 Net Income (TTM) (Millions $) -143
 Cash Flow (TTM) (Millions $) -78
 Capital Exp. (TTM) (Millions $) 26

Lucira Health Inc
Lucira Health Inc.
is a medical technology company based in the United States that focuses on developing and commercializing innovative technologies for healthcare providers and consumers.
The company specializes in the areas of molecular diagnostics, mobile health, and medical devices.
The company is best known for its Lucira Check-It COVID-19 At-Home Test Kit, a single-use, molecular test designed to detect the presence of the virus that causes COVID-19.The Lucira Check-It COVID-19 At-Home Test Kit is a portable, quick, and easy-to-use at-home test that helps individuals self-diagnose COVID-19 within 30 minutes.
The test is authorized for emergency use in the United States by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) and is the first COVID-19 test that is fully self-contained, enabling users to complete the entire testing process at home without needing to send their samples to a laboratory.Lucira Health Inc.
was founded in 2013 and is headquartered in Emeryville, California.
The company has partnerships with several healthcare and biotech companies, including Abbott and JSR Life Sciences, to optimize its diagnostic technology and expand its market reach.
In addition to its COVID-19 test, the company is also developing other diagnostic products that focus on infectious diseases, cancer, and women's health.


   Company Address: 1412 62nd Street Emeryville 94608 CA
   Company Phone Number: 350-8071   Stock Exchange / Ticker: NASDAQ LHDX
   LHDX is expected to report next financial results on November 13, 2023.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Meridian Bioscience Inc

VIVO has Slipped into deficit at the In Vitro and In Vivo Diagnostic Substances company all along the fiscal first quarter of 2023

Meridian Bioscience Inc reported disappointing first quarter of 2023 financial report, where Revenue melted down by -35.588 % to $56.90 million and the In Vitro and In Vivo Diagnostic Substances company posted net deficit per share to $-0.68, in contrast to $0.35, in the financial interval ending December 31 2021. On the contrary to the In Vitro and In Vivo Diagnostic Substances company's scenario the on averageIn Vitro and In Vivo Diagnostic Substances industry, posted a top-line 27.43% improvement compared to the comparable period a year before in the first quarter of 2023.

Biomerica Inc

Biomerica Inc: Losses Narrow but Revenue Plummets Amid Investor Concerns for Future Performance

Biomerica Inc Faces Challenges as Revenue Falls and Losses Widen
Investors in Biomerica Inc are facing a challenging period, as the company reported a decline in revenue and widening losses for the March to May 31, 2023 time-frame. The company's financial performance has raised concerns among investors who are now questioning the future prospects of the company.
In terms of earnings per share, Biomerica Inc managed to improve, with a loss per share decreasing from $-0.14 to $-0.10 compared to the previous year. However, the company's revenue fell sharply by -79.099% from $5.30 million to $1.11 million, indicating a significant decline in sales for the comparable reporting season. Sequentially, revenue also decreased by -0.291%.
Quotient Limited

The In Vitro and In Vivo Diagnostic Substances company announced that revenue decreased softly , during the third quarter of 2023 earnings season

Lower revenue led to diminishing Returns in the October to December 31 2022 time-frame, Revenue diminished by -4.405 % to $9.05 million and deficit per share was at $-3.13 in contrast to $-0.28 per share realized in the quarter a year before. In contrast to the the Quotient Limiteds' scenario the rest ofIn Vitro and In Vivo Diagnostic Substances sector, posted a top-line 27.43% rise compared to the same period a year before in the third quarter of 2023.

Oncocyte Corporation

Oncocyte Corporation Stumbles as Revenues Plummet 57.562% in Q2 2023, Raising Investor Alarm



In the wake of the most recent fiscal period, Oncocyte Corporation has unveiled concerning financial results, reporting a drastic decline in revenue and a significant increase in net loss per share. While the rest of the In Vitro and In Vivo Diagnostic Substances sector saw positive growth, Oncocyte Corporation struggled to maintain its foothold. This article seeks to shed light on the implications of the company's performance and its contrasting market sentiment.
Revenues and Net Loss Per Share:
Oncocyte Corporation's revenues plummeted by an alarming 57.562% to a mere $0.46 million in the most recent fiscal period. This decrease is significant, especially when compared to the corresponding financial report from the previous year. The net loss per share also stands out, swelling to $-1.07, further amplifying concerns among investors.
Neogen Corporation

Neogen Corporation Achieves Remarkable 72.256% Revenue Surge Throughout Q1-Q2 2023

Over the past five trading days, the stock of Neogen Corporation has experienced a decline of -4.7%. This brings the year-to-date performance of the stock to 47.44%. Additionally, the stock is currently 6.6% short off its 52-week high.
In its May 31, 2023 report, Neogen Corporation announced a net profit per share of $0.02 and revenue of $218.26 million. This reflects a sharp decline in income compared to the fourth quarter of 2022 when the company earned $0.14 EPS. However, during the same period, revenue rose by an impressive 72.256%. Neogen Corporation has clearly outperformed its peers in the In Vitro and In Vivo Diagnostic Substances sector, which only showed 12.35% revenue growth during this time.





 

Lucira Health Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com